WS
ABBV icon

Wela Strategies’s AbbVie ABBV Stock Holding History

Wela Strategies’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$688K Buy
+2,970
New +$605K 0.26% 31

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wela Strategies's ABBV Position: Q3 2025 in Review

Wela Strategies opened a new position in AbbVie (ABBV) in Q3 2025: 2,970 shares worth $688K. The stake represents 0.26% of the portfolio and ranks #31 among its holdings.

3,906 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Wela Strategies held 2,970 shares of AbbVie worth $688K as of Q3 2025.
  • AbbVie was a new Wela Strategies position in Q3 2025.
  • AbbVie made up 0.26% of Wela Strategies's portfolio in Q3 2025, its #31 holding.
  • 3,906 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Wela Strategies's 13F filing for Q3 2025, filed 24 Oct 2025.